Explore 3 Stock Ideas & Industry Insights Download Free Report
HUTCHMED (China) Limited, which is quoted on AIM andNasdaqunder the ticker LSE:HCM and on the Hong Kong exchange under code 13, announced that AstraZeneca has filed aNew Drug Application (NDA)with the FDA for the combination of ORPATHYS and TAGRISSO.
•Proteome Sciences plc is being watched because a proteomics and life-sciences company providing contract research, biomarker and mass-spectrometry services for drug discovery and development.
•TheraCryf plc is being watched because a clinical-stage biotechnology company developing medicines for addiction and other neuropsychiatric disorders.
•NIOX Group plc is being watched because a medical-device company focused on point-of-care fractional exhaled nitric oxide testing for asthma and COPD management.
•MicroSalt plc is being watched because a food-technology company commercialising patented low-sodium salt designed to deliver familiar salt flavour with materially reduced sodium.
Ondine Biomedical Inc. (LSE:OBI) said on 29 September 2026 that it has entered a strategic data evaluationPartnershipwith Mela Solutions Ltd. The aim is to measure the financial and clinical impact of Steriwave across NHS intensive care units and to "verify Steriwave's cost-benefit ratio".
JPMorgan, which rates Haleon underweight, placed the stock on negative catalyst watch ahead of its third-quarter results, scheduled for 29 October. A negative catalyst watch indicates that the bank expects the upcoming results to be a disappointment that could weigh on the share price.
Venture Life published final results for the 17 months ended 31 May 2026, following a change in its accounting reference date from 31 December to 31 May. The comparative figures are for the 12 months to 31 December 2024, so the headline numbers are …
NIOX Group (LSE:NIOX), which makes point-of-care FeNO testing devices used in the diagnosis and management of asthma and COPD, published interim results for the six months to 30 June 2026 and, in a separate announcement, a proposed tender offer.
•The company is developing a clinical and preclinical pipeline focused on brain disorders.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…